Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 9, 2016, Pages

  Chiang, C Y ^a,b,c   Van Deun, A ^a,d   Rieder, H L ^e  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b Wan Fang Hospital   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Dysglycaemia; GFX; Multidrug resistance; Tuberculosis

Indexed keywords

GATIFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DYSGLYCEMIA; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; BANGLADESH; CAMEROON; GLUCOSE BLOOD LEVEL; METABOLISM; MICROBIOLOGY; NIGER; PILOT STUDY; PREVALENCE; SPUTUM;

ANTITUBERCULAR AGENTS; BANGLADESH; BLOOD GLUCOSE; CAMEROON; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROQUINOLONES; HUMANS; NIGER; PILOT PROJECTS; PREVALENCE; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84982166084     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0884     Document Type: Review

References (32)

1. Van Deun A, Aung K J M, Halim M A, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
2. Aung K J M, Van Deun A, Declercq E, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180-1187.
3. Piubello A, Hassane Harouna S, Souleymane M B, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188-1194.
4. Kuaban C, Noeske J, Rieder H L, Aït-Khaled N, Abena Foe J L, Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 517-524.
5. Ahuja S D, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLOS Med 2012; 9: e1001300.
6. World Health Organization. Global tuberculosis report, 2015. WHO/HTM/TB/2015.22. Geneva, Switzerland: WHO, 2015.
7. Mitchison D.A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-225.
8. Johnson J L, Hadad D J, Boom W H, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10: 605-612.
9. Donald P R, Diacon A H. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis 2008; 88 (SUPPL. 1): S75-S83.
10. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2003; 47: 3117-3122.
11. Ahmad Z, Tyagi S, Minkowski A, Peloquin C A, Grosset J H, Nuermberger E L. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. Am J Respir Crit Care Med 2013; 188: 97-102.
12. Hu Y, Coates A R M. Mitchison D A. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 653-657.
13. Gumbo T, Louie A, Parsons L M, Salfinger M, Drusano G L. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-1651.
14. Cegielski J P, Dalton T, Yagui T, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014; 59: 1049-1063.
15. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011: pp 1-33.
16. Grosset J H, Tyagi S, Almeida D V, et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 2013; 188: 608-612.
17. Tyagi S, Ammerman N C, Li S Y, et al. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci 2015; 112: 869-874.
18. Swanson R V, Adamson J, Moodley C, et al. Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis. Antimicrob Agents Chemother 2015; 59: 3042-4051.
19. Xu J, Lu Y, Fu L, et al. In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters. Int J Tuberc Lung Dis 2012; 16: 1119-1125.
20. Pietersen E, Ignatius E, Streicher E M, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014; 383: 1230-1239.
21. Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 2015; 60: 1361-1367.
22. Nunn A J, Rusen I D, Van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials 2014; 15: 353.
23. Owens RC, Jr., Ambrose P G. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 (SUPPL. 2): S144-S157.
24. Park-Wyllie L Y, Juurlink D N, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354: 1352-1361.
25. Gurwitz J.H. Serious adverse drug effects-seeing the trees through the forest. (Editorial). N Engl J Med 2006; 354: 1413-1415.
26. US Food and Drug Administration. Gatifloxacin (marketed as Tequin®) Information. Rockville, MD, USA: FDA, 2006. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm107821.htm. Accessed June 2016.
27. Mehlhorn A J, Brown D A. Safety concerns with fluoroquinolones. Ann Pharmacother 2007; 41: 1859-1866.
28. Chou H W, Wang J L, Chang C H, Lee J J, Shau W Y, Lai M S. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Clin Infect Dis 2013; 57: 971-980.
29. Ginsburg A S, Grosset J H, Bishai W R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3: 432-442.
30. Rigouts L, Coeck N, Gumusboga M, et al. Specific gyrA gene mutations predict poor treatment outcome in multidrug-resistant tuberculosis. J Antimicrob Chemother 2016; 71: 314-324.
31. Falagas M E, Rafailidis P I, Rosmarakis E S. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007; 29: 374-379.
32. Lapi F, Wilchesky M, Kezouh A, Benisty J I, Ernst P, Suissa S. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis 2012; 55: 1457-1465.